A new GLP-1 pill, orforglipron, produced stronger weight loss in people with type 2 diabetes.
Participants lost up to eight percent of body weight during a one-year phase 3 trial.
The drug activates GLP-1 receptors to lower blood sugar and reduce appetite.
Patients can take it without fasting, which simplifies daily use.
Researchers studied more than 1,500 adults across multiple countries.
They compared two doses of orforglipron with oral semaglutide.
Orforglipron improved glucose control and outperformed semaglutide in weight reduction.
More patients stopped the new drug because of gastrointestinal side effects.
Discontinuation reached about ten percent in the orforglipron groups.
Regulators still review the tablet for market approval.
Experts expect effective pills to expand access because they are easier to store and take.
Scientists stress the need for long-term safety data.
They believe incretin-based therapies could soon become first-line diabetes treatment.
